Mitochondrial dysfunction claims on TikTok: what peptide promoters get wrong

What's this video probably claiming?

Based on the caption and the creator's category focus on peptide therapy, this video is almost certainly doing two things at once. First, it's describing a constellation of vague symptoms, fatigue, brain fog, weakness, and cognitive impairment, under the umbrella of "mitochondrial dysfunction." Second, given that this content falls under the peptide therapy category, there's a strong likelihood the video is implying or directly suggesting that peptides like BPC-157, GHK-Cu, or semax can address this "hidden condition." The framing of mitochondrial dysfunction as mysterious and underdiagnosed is a well-worn setup for selling interventions that lack regulatory approval for this purpose. Calling it a "hidden condition" is a red flag. Primary mitochondrial diseases are rare, genetically confirmed disorders. The casual use of the term to describe everyday fatigue is a significant clinical leap that deserves scrutiny.

What does the science actually show?

Primary mitochondrial diseases are genuinely serious, affecting roughly 1 in 5,000 people, according to Gorman et al. (2016, Nature Reviews Disease Primers). These are confirmed via genetic testing and specific biomarkers like elevated lactate and pyruvate ratios, not symptom checklists. The peptides commonly promoted alongside this framing have a far thinner evidence base. BPC-157 has shown mitochondrial-protective effects in rodent models of oxidative stress (Sikiric et al., 2018, Current Pharmaceutical Design), but zero peer-reviewed human trials demonstrate it treats mitochondrial dysfunction clinically. GHK-Cu has demonstrated some cellular activity in fibroblast studies (Pickart and Margolina, 2018, Symmetry), but again, no human RCTs connect it to measurable mitochondrial outcomes. MK-677, a growth hormone secretagogue, showed modest lean mass improvements in older adults (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism), but not mitochondrial repair. The gap between animal data and human clinical evidence here is enormous.

Where does the social media noise diverge from clinical reality?

The TikTok version of mitochondrial dysfunction has become a catch-all diagnosis for symptoms that have dozens of legitimate explanations: thyroid disorders, iron deficiency, sleep apnea, depression, or simple deconditioning. Neurologists and metabolic disease specialists spend years ruling out these causes before landing on a mitochondrial etiology. What social media creators do instead is describe generic fatigue and cognitive symptoms, attach a scientific-sounding mechanism, and then position peptides or supplement stacks as the fix. This is not medicine. It is pattern-matching for engagement. The creator's hashtag use of "doctorsoftiktok" does confer a layer of perceived authority, but physician status does not exempt someone from the obligation to distinguish between animal data, preliminary research, and established clinical practice. Semax and selank, two peptides frequently bundled into this narrative, have primarily Soviet-era clinical literature that has not been independently replicated in Western peer-reviewed trials to any meaningful scale.

What should you actually know?

If you genuinely have persistent fatigue, weakness, and cognitive symptoms, the first stop is a primary care physician who will run a full metabolic panel, thyroid function tests, CBC, ferritin, B12, and sleep evaluation before anyone should mention mitochondria. True mitochondrial disease requires specialist evaluation, often including muscle biopsy and whole-exome sequencing. No compounded peptide has been approved by the FDA to treat mitochondrial dysfunction. As of 2023, the FDA has placed BPC-157 and several other peptides on the list of substances that cannot be compounded under 503A or 503B regulations, citing insufficient evidence of safety and effectiveness. If a provider is selling you a peptide protocol for "mitochondrial support" without prior diagnostic workup, that is a commercial arrangement dressed as clinical care. Ask for the evidence. Ask what your mitochondrial biomarkers actually are before accepting this framing.